CLE-100
Major Depressive Disorder
Phase 2Active
Key Facts
About Clexio Biosciences
Israeli biotech developing NMDA‑antagonist and KV7‑channel therapies for depression and epilepsy.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| Proliv™Rx | Neurolief | Phase 2 |